CANCER RELATED
ANOREXIA-CACHEXIA
SYNDROME (CACS):
CACS affects ~70-80% of patients in the advanced stages
Symptoms:
- progressive weight loss & loss of appetite,
- skeletal muscle wasting & reduced adipose tissue,
- involuntary loss of more than 10% of the original weight
CACS adversely affects a patient’s quality of life,
and negatively predicts treatment outcome


CANNABICS™ SR
FOR TREATMENT OF CACS
Drug candidate for palliative treatment of Cancer related Anorexia-Cachexia
Syndrome (CACS)
Proprietary formulation
*patent pending
Extended release oral capsule
Clinically tested for the treatment of CACS:
- therapeutic effect of 8-10 hrs.
- low dosage of psychoactive ingredient
- no significant side effects
CLINICAL STUDY (Pilot Study)
Tested doses:
5mgX1 or 5mgX2 capsules daily
5mgX1 or 5mgX2 capsules daily
Study Conclusions:
- A weight increase of ≥10% in 17.6% of patients
- No significant side effects
- The results justify a larger study with dosage-controlled
cannabis capsules in CACS
